MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol. 2020 Mar;21(3):373-386.
[1] Zhi Peng, et al. Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC)...
MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 Mar;21(3):373-386.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol (2020) 21(3):373–86. doi: 10.1016/S1470-2045(...
October 12, 2024 Commentary Video Telisotuzumab adizutecan (ABBV-400) is a novel antibody-drug conjugate (ADC) targeting the c-Met protein, which is overexpressed in several cancers, including gastroesophageal junction (GEJ) adenocarcinoma. This ADC is being investigated in a phase 1 clinical tr...
8.Wu YL,Guarneri V,Voon PJ,et al.Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib(INSIGHT 2):a multicentre,open-label,phase 2 trial.LANCET ONCOLOGY.2024;25(8):989-1002....
8.Wu YL,Guarneri V,Voon PJ,et al.Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib(INSIGHT 2):a multicentre,open-label,phase 2 trial.LANCET ONCOLOGY.2024;25(8):989-1002....
cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase ...
1、「右上肺」肺浸润性腺癌(腺泡生长型,两个病灶直径分别为 1.5 cm 和 1.6 cm)。 2、支气管切缘阴性。 3、「第 2,4 组」淋巴结(0/3)、「第 4 组」淋巴结(0/1)、「第 7 组」淋巴结(0/3)、「第 10 组」淋巴结(0/2)、「第 11 组」淋巴结(0/2)未见癌转移。免疫组化:甲状腺转录因子 1(...
[11] Hartmaier R,et al. Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study.Cancer Res15 June 2022; 82 (12_Suppl...